Rachael F F Grace

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1101738/publications.pdf

Version: 2024-02-01

86 papers	2,776 citations	218381 26 h-index	189595 50 g-index
88 all docs	88 docs citations	88 times ranked	2897 citing authors

#	Article	IF	Citations
1	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. Blood Advances, 2022, 6, 1844-1853.	2.5	12
2	Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant. Pediatric Blood and Cancer, 2022, 69, e29410.	0.8	1
3	Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (<scp>PKD</scp>)?: Toward an expanded definition of severe <scp>PKD</scp>. American Journal of Hematology, 2022, 97, .	2.0	3
4	Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and metaâ€analysis of prospective clinical trials. Pediatric Blood and Cancer, 2022, 69, e29447.	0.8	6
5	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. New England Journal of Medicine, 2022, 386, 1432-1442.	13.9	42
6	Diagnosis, monitoring, and management of pyruvate kinase deficiency in children. Pediatric Blood and Cancer, 2022, 69, e29696.	0.8	1
7	SARSâ€CoVâ€2 vaccination in pediatric patients with immune thrombocytopenia. Pediatric Blood and Cancer, 2022, 69, e29760.	0.8	3
8	The pyruvate kinase (PK) to hexokinase enzyme activity ratio andÂerythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. British Journal of Haematology, 2021, 192, 1092-1096.	1.2	15
9	International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. Journal of Thrombosis and Haemostasis, 2021, 19, 287-296.	1.9	13
10	Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 69-80.	1.0	13
11	Comorbidities and complications in adults with pyruvate kinase deficiency. European Journal of Haematology, 2021, 106, 484-492.	1.1	17
12	Quality of life is an important indication for secondâ€line treatment in children with immune thrombocytopenia. Pediatric Blood and Cancer, 2021, 68, e29023.	0.8	4
13	Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. European Journal of Haematology, 2021, 106, 783-787.	1.1	9
14	Preoperative hematocrit and platelet count are associated with blood loss during spinal fusion for children with neuromuscular scoliosis. Journal of Perioperative Practice, 2021, , 175045892096263.	0.3	1
15	Recommendations for the clinical and laboratory diagnosis of VITT against COVIDâ€19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 1585-1588.	1.9	127
16	The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. Journal of Thrombosis and Haemostasis, 2021, 19, 2094-2095.	1.9	4
17	Pyruvate kinase deficiency in children. Pediatric Blood and Cancer, 2021, 68, e29148.	0.8	10
18	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 2348-2354.	1.9	7

#	Article	IF	Citations
19	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 2082-2088.	1.9	14
20	Response to rituximab in children and adults with immune thrombocytopenia (ITP). Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12587.	1.0	4
21	Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open, 2021, 11, e044885.	0.8	2
22	An Update on Pediatric Immune Thrombocytopenia (ITP): Differentiating Primary ITP, IPD, and PID. Blood, 2021, , .	0.6	8
23	Survey of 275 Patients and Caregivers Affected By Pyruvate Kinase Deficiency: Impact of Communication with Hematologists on Mental Health and Quality of Life. Blood, 2021, 138, 1948-1948.	0.6	0
24	Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-Term Treatment with Mitapivat. Blood, 2021, 138, 924-924.	0.6	3
25	Characterizing Iron Overload By Age in Patients Diagnosed with Pyruvate Kinase Deficiency - a Descriptive Analysis from the Peak Registry. Blood, 2021, 138, 3074-3074.	0.6	0
26	Rationale and Design of a Phase 3b Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel-Group Trial with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Pediatric Patients with Immune Thrombocytopenia. Blood, 2021, 138, 4211-4211.	0.6	1
27	Standardizing the Diagnostic and Therapeutic Approach to Newly Diagnosed Children with ITP: An ITP Consortium of North America (ICON) Quality Improvement Initiative. Blood, 2021, 138, 755-755.	0.6	1
28	Genetic variants in tollâ€like receptor 4 are associated with lack of steroidâ€responsiveness in pediatric ITP patients. American Journal of Hematology, 2020, 95, 395-400.	2.0	4
29	Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Diseaseâ€specific assessments. European Journal of Haematology, 2020, 104, 427-434.	1.1	9
30	Pyruvate kinase deficiency in a newborn with extramedullary hematopoiesis in the skin. Blood, 2020, 136, 770-770.	0.6	1
31	Management of pyruvate kinase deficiency in children and adults. Blood, 2020, 136, 1241-1249.	0.6	42
32	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	2.0	8
33	Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. Journal of Allergy and Clinical Immunology, 2020, 146, 1194-1200.e1.	1.5	92
34	The role of romiplostim for pediatric patients with immune thrombocytopenia. Therapeutic Advances in Hematology, 2020, 11, 204062072091299.	1.1	19
35	COVIDâ€19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation. Pediatric Blood and Cancer, 2020, 67, e28382.	0.8	32
36	Fatigue in children and adolescents with immune thrombocytopenia. British Journal of Haematology, 2020, 191, 98-106.	1.2	18

#	Article	IF	Citations
37	Genotypeâ€phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, 472-482.	2.0	47
38	The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica, 2020, 105, 2229-2239.	1.7	30
39	Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature. Blood, 2020, 136, 45-46.	0.6	1
40	Characteristics of Children and Adults Treated with Rituximab for Immune Thrombocytopenia (ITP). Blood, 2020, 136, 38-39.	0.6	0
41	Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method. Blood, 2020, 136, 6-8.	0.6	0
42	Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. New England Journal of Medicine, 2019, 381, 933-944.	13.9	115
43	Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multiâ€institutional review. American Journal of Hematology, 2019, 94, 461-466.	2.0	8
44	How we manage patients with pyruvate kinase deficiency. British Journal of Haematology, 2019, 184, 721-734.	1.2	66
45	Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. American Journal of Hematology, 2019, 94, 741-750.	2.0	37
46	Pediatric Hematology. Hematology/Oncology Clinics of North America, 2019, 33, xiii-xiv.	0.9	1
47	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	2.5	684
48	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	1.7	46
49	The Effect of "Pathway" to Diagnosis for Childhood ITP on Caregiver Quality of Life at Time of Diagnosis. Blood, 2019, 134, 2174-2174.	0.6	1
50	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888.	2.0	30
51	The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. Journal of Thrombosis and Thrombolysis, 2018, 45, 306-314.	1.0	31
52	Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Thrombolysis, 2018, 46, 81-83.	1.0	13
53	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192.	0.6	121
54	Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatric Blood and Cancer, 2018, 65, e26736.	0.8	51

#	Article	IF	Citations
55	Red Blood Cell Enzyme Disorders. Pediatric Clinics of North America, 2018, 65, 579-595.	0.9	47
56	The burden of disease in pyruvate kinase deficiency: Patientsâ€™ perception of the impact on healthâ€related quality of life. European Journal of Haematology, 2018, 101, 758-765.	1.1	25
57	Pklr Intron Splicing-Associated Mutations and Alternate Diagnoses Are Common in Pyruvate Kinase Deficient Patients with Single or No Pklr Coding Mutations. Blood, 2018, 132, 3607-3607.	0.6	4
58	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807.	0.6	1
59	Increasing observation rates in lowâ€risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP^{Â®}). Pediatric Blood and Cancer, 2017, 64, e26303.	0.8	14
60	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatric Blood and Cancer, 2016, 63, 1407-1413.	0.8	70
61	Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia. Journal of Physical Education and Sports Management, 2016, 2, a000885.	0.5	10
62	Second-line therapies in immune thrombocytopenia. Hematology American Society of Hematology Education Program, 2016, 2016, 698-706.	0.9	32
63	Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatric Neurology, 2016, 62, 66-70.	1.0	5
64	Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study. Blood, 2016, 128, 402-402.	0.6	5
65	Erythrocyte pyruvate kinase deficiency: 2015 status report. American Journal of Hematology, 2015, 90, 825-830.	2.0	140
66	Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood, 2015, 126, 873-879.	0.6	124
67	Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatric Blood and Cancer, 2015, 62, 214-218.	0.8	31
68	Thrombopoietin-receptor agonists in children with immune thrombocytopenia. Lancet, The, 2015, 386, 1606-1609.	6.3	3
69	The utility of the DDAVP challenge test in children with low von Willebrand factor. British Journal of Haematology, 2015, 170, 884-886.	1.2	5
70	Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants. Blood, 2015, 126, 3337-3337.	0.6	4
71	DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency. Blood, 2015, 126, 4548-4548.	0.6	1
72	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood, 2015, 126, 73-73.	0.6	6

#	Article	IF	Citations
73	The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. Blood, 2015, 126, 2136-2136.	0.6	1
74	The use of erythropoietinâ€stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience. European Journal of Haematology, 2014, 93, 161-164.	1.1	9
75	Standardized Clinical Assessment and Management Plans (SCAMPs): Perspectives on a New Method to Understand Treatment Decisions and Outcomes in Immune Thrombocytopenia. Seminars in Hematology, 2013, 50, S31-S38.	1.8	4
76	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 2012, 119, 3263-3268.	0.6	48
77	Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. Pediatric Blood and Cancer, 2012, 58, 216-220.	0.8	17
78	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatric Blood and Cancer, 2012, 58, 221-225.	0.8	29
79	Trends in anti-D immune globulin for childhood immune thrombocytopenia: Usage, response rates, and adverse effects. American Journal of Hematology, 2012, 87, 315-317.	2.0	15
80	The frequency and management of asparaginaseâ€related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Danaâ€Farber Cancer Institute consortium protocols. British Journal of Haematology, 2011, 152, 452-459.	1.2	216
81	Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. American Journal of Hematology, 2010, 85, 135-137.	2.0	3
82	Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Annals of Hematology, 2010, 89, 95-103.	0.8	47
83	Unsuspected Pulmonary Emboli in Pediatric Oncology Patients: Detection With MDCT. American Journal of Roentgenology, 2010, 194, 1216-1222.	1.0	20
84	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood, 2010, 116, 2509-2509.	0.6	0
85	Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. Pediatric Blood and Cancer, 2009, 52, 865-867.	0.8	10
86	Compliance with Immunizations in Splenectomized Individuals: A Study of the Splenectomized Hereditary Spherocytosis Population. Blood, 2008, 112, 1316-1316.	0.6	1